Your browser doesn't support javascript.
loading
Alpha-1 antitrypsin inhibits SARS-CoV-2 infection
Lukas Wettstein; Carina Conzelmann; Janis A Mueller; Tatjana Weil; Ruediger Gross; Maximilian Hirschenberger; Alina Seidel; Susanne Klute; caterina Prelli-Bozzo; Fabian Zech; Nico Preising; Giorgio Fois; Robin Lochbaum; Philip Knaff; Volker Mailaender; Ludger Staendker; Dietmar Thal; Christian Schumann; Steffen Stenger; Konstantin Sparrer; Alexander Kleger; Guenter Lochnit; Frank Kirchhoff; Manfred Frick; Jan Muench.
Afiliación
  • Lukas Wettstein; Ulm University
  • Carina Conzelmann; Ulm University
  • Janis A Mueller; Ulm University
  • Tatjana Weil; Ulm University
  • Ruediger Gross; Ulm University
  • Maximilian Hirschenberger; Ulm University
  • Alina Seidel; Ulm University
  • Susanne Klute; Ulm University
  • caterina Prelli-Bozzo; Ulm University
  • Fabian Zech; Ulm University
  • Nico Preising; Ulm University
  • Giorgio Fois; Ulm University
  • Robin Lochbaum; Ulm University
  • Philip Knaff; MPI Mainz
  • Volker Mailaender; MPI Mainz
  • Ludger Staendker; Ulm University
  • Dietmar Thal; University Ulm
  • Christian Schumann; Clinics Kempten- Allgaeu
  • Steffen Stenger; Ulm University
  • Konstantin Sparrer; Ulm University
  • Alexander Kleger; Ulm University
  • Guenter Lochnit; University Giessen
  • Frank Kirchhoff; Ulm University
  • Manfred Frick; Ulm University
  • Jan Muench; Ulm University
Preprint en En | PREPRINT-BIORXIV | ID: ppbiorxiv-183764
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified 1-antitrypsin (1-AT) as specific inhibitor of SARS-CoV-2. 1-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations. Our findings show that endogenous 1-AT restricts SARS-CoV-2 and repurposes 1-AT-based drugs for COVID-19 therapy.
Licencia
cc_no
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Idioma: En Año: 2020 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Idioma: En Año: 2020 Tipo del documento: Preprint